Ask about this productRelated genes to: LGALS9 Blocking Peptide
- Gene:
- LGALS9 NIH gene
- Name:
- galectin 9
- Previous symbol:
- -
- Synonyms:
- LGALS9A
- Chromosome:
- 17q11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1997-06-25
- Date modifiied:
- 2016-05-13
Related products to: LGALS9 Blocking Peptide
Related articles to: LGALS9 Blocking Peptide
- Neonatal sepsis remains a leading cause of infant mortality, yet mechanisms driving concurrent hyperinflammation and immunosuppression remain unclear. Here, we perform single-cell RNA sequencing on 26 blood samples from 18 neonates, spanning acute sepsis, convalescence, and healthy controls. We identify 57 cell subtypes, revealing acute lymphoid depletion and myeloid expansion. S100A8 myeloid-derived suppressor cell-like (MDSC-like) cells represent a putative cytokine-storm source, potentially amplified by a feedforward S100-TLR4-MYD88 circuit. Innate-like lymphocytes fail to expand, succumbing to apoptosis and exhaustion despite heightened cytotoxicity. CD4 T cells display mitochondrial dysfunction, while regulatory T cells acquire a hyper-suppressive phenotype via the LGALS9-HAVCR2 axis. CD8 T cells undergo interferon-driven, innate-like reprogramming before lapsing into exhaustion, and B cells shift toward stress-adaptive, tolerogenic states. Together, our atlas defines a dual pathology in which MDSC-like cell-driven cytokine storm coexists with multi-lineage immunoparalysis, nominating the S100-TLR4 axis and mitochondrial dysregulation as potential therapeutic targets. - Source: PubMed
Publication date: 2026/08/24
Wang JieChen YingZou PeicenDu YueLi YingZhang LiZhou JuanWan LinglongXu YifeiWang YiWang YajuanMeng Lihui - Most transcriptomic studies in acute myeloid leukemia (AML) have focused on transcriptional regulation, whereas the clinical and biological relevance of translation initiation factors remains insufficiently defined. Eukaryotic translation initiation factor 2 subunit alpha () is a key regulator of translation initiation, but its prognostic significance and association with AML remain unclear. - Source: PubMed
Publication date: 2026/08/05
Hong XiaoyingHuang YingyingWu WeiJiang XiandongLin YanfengXue YanLin Donghong - Immunotherapeutic approaches for cutaneous squamous cell carcinoma (cSCC) remain limited to programmed cell death protein 1 (PD-1) blockade. Although genomics studies have characterized key driver mutations in cSCC, preclinical models that faithfully recapitulate both the genetic landscape and immune microenvironment of the human disease, that could drive the development of novel, effective therapies, are lacking. - Source: PubMed
Publication date: 2026/08/13
Rodriguez Rosario Alanis ERangel RobertoBalbin NicholasNizami Zohra NHadi JaafarNoor AhmedDong LipingCorona ArnoldoBhavani NikithaCruz Sanchez Ricardo MSunga Gemalene MVeeramachaneni RatnaManyam Ganiraju CWang JingYu WendongSikora Andrew GN Myers JeffreyRangel Roberto - Lung cancer (LC) is a leading cause of cancer-related death. Microwave ablation (MWA) is a promising local therapy, but its impact on systemic immunity remains unclear. - Source: PubMed
Publication date: 2026/07/30
Wu YuesongWei XiaolongYang WentaoWang FengpingWang JianchunHuang ZhiZou FengxiangLiu Jianqun - The tumor microenvironment, particularly the tumor stroma, plays a critical role in tumor progression, immune evasion, and therapeutic resistance. However, its interaction with the immune landscape in rectal cancer (RC) remains incompletely understood. This study aimed to comprehensively characterize the stromal-immune ecosystem associated with the tumor stroma ratio (TSR) in RC and to evaluate its clinical and therapeutic relevance. - Source: PubMed
Publication date: 2026/08/03
Wang QianyuTian NaGuo HanchuanXiang YingshiXiao YiLin GuoleZhang GuannanXu LaiLu JunyangChen GangCai HuiyunDu XiaohuiDu JunfengWu Bin